

ALLERGAN INC  
Form 8-K  
October 14, 2003

Table of Contents

---

**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**  
**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities and Exchange Act of 1934**

**Date of Report** (Date of earliest event reported):  
**October 13, 2003**

**ALLERGAN, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**1-10269**  
(Commission File  
Number)

**95-1622442**  
(IRS Employer  
Identification Number)

**2525 Dupont Drive**  
**Irvine, California**  
(Address of principal executive  
offices)

**92612**  
(Zip Code)

**(714) 246-4500**

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On October 14, 2003, Allergan, Inc., a Delaware corporation ( Allergan ), announced the execution of an Agreement and Plan of Merger, dated as of October 13, 2003 (the Merger Agreement ), by and among Allergan, Wilson Acquisition, Inc., a California corporation and wholly-owned subsidiary of Allergan ( Merger Sub ), and Oculex Pharmaceuticals, Inc., a California corporation ( Oculex ). Pursuant to the Merger Agreement, Merger Sub will merge with and into Oculex, with Oculex surviving and becoming a wholly-owned subsidiary of Allergan.

A copy of Allergan s press release dated October 14, 2003 announcing the execution of the Merger Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) Exhibits

99.1 Allergan, Inc. Press Release dated October 14, 2003.

---



**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Allergan, Inc. Press Release dated October 14, 2003.